Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition - 2Satellites capture aftermath of Ethiopian volcano's 1st eruption in recorded history (images)
- 3Nitty gritty Manual for Picking Agreeable Tennis shoes
- 4A throat bone settles it - Nanotyrannus was not a juvenile T. rex
- 5'A completely new manufacturing frontier': Space Forge fires up 1st commercial semiconductor factory in space
- Health officials report 14 Legionnaires' disease cases in Florida, gym connection suspected
- Esteem Stuffed Gaming Workstations to Consider
- Merz: 80% of Syrians in Germany should return in three years
- Pick Your Favored pizza beating
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- Pick Your Favored kind of sandwich
- China's 'Venice Of The East' Is A Historic Canal City Near Shanghai With Arched Bridges And Lantern-Lit Waterways
- A Couple of Modest Guitars for 2024
